TrialsgrambetaRCTs are beautiful

NefIgArd

2023

Nefecon in Patients with Primary IgA Nephropathy

In 364 patients with IgA nephropathy on optimised RAS blockade, targeted-release budesonide preserved eGFR and reduced proteinuria compared with placebo.

Result

Primary endpoint: Time-weighted eGFR over 2 years

+5.1 mL/min/1.73m² versus placebo (p<0.001); proteinuria reduced 41%.

Original publication
Subtopic
IgA nephropathy
Design
Phase 3 double-blind RCT
Relevance
Important: one of several pillars.
Source
Lafayette R, et al. Lancet. 2023;402(10405):859-870.doi 10.1016/S0140-6736(23)01554-4

Discussion & critique

Led to full FDA approval of Tarpeyo; off-drug follow-up and steroid-type adverse effects temper enthusiasm.

Discussed in podcasts